onc Videos

Videos

Videos

Treating a Patient With Lower-Risk Myelodysplastic Syndrome

07/12/2023

Amer Zeidan, MBBS, highlights his treatment choices for the case of a 74-year-old patient diagnosed with lower-risk myelodysplastic syndrome (MDS).

Amer Zeidan, MBBS, highlights...

07/12/2023

Oncology

Lucjan Wyrwicz, MD, Maria Sklodowska Curie National Cancer Research Institute

Videos

Continued Benefit From Pembrolizumab Plus Chemotherapy in Later-Line Therapy for Patients With Advanced, HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma

07/12/2023

L. Wyrwicz ;

At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal...

At the 2023 World Congress on...

07/12/2023

Oncology

James Harding, MD, Memorial Sloan Kettering Cancer Center

Videos

Novel Dual IDH-Inhibitor Plus Chemotherapy Showed Promising Efficacy, Safety for Patients With Advanced IDH-Mutant Cholangiocarcinoma

07/12/2023

J. Harding ;

According to a study presented at the 2023 World Congress on Gastrointestinal Cancers, the IDH1/2-inhibitor LY3410738 showed promising efficacy and safety in combination with chemotherapy for patients with locally advanced or metastatic...

According to a study presented...

07/12/2023

Oncology

Videos

Tafasitamab Plus Lenalidomide Therapy Demonstrates Prolonged, Durable Responses for Patients With R/R DLBCL

07/11/2023

Nagesh Kalakonda , MD;

Nagesh Kalakonda, MD, discusses final results from the L-MIND study, in which the combination of tafasitamab plus lenalidomide demonstrated durable responses and curative potential for patients with R/R DLBCL.

Nagesh Kalakonda, MD, discusses...

07/11/2023

Oncology

Videos

Post-Transplantation Cyclophosphamide, Tacrolimus, Mycophenolate and Mofetil vs Standard Prophylaxis for Patients With GVHD

07/10/2023

Javier Bolaños Meade , MD;

Javier Bolaños Meade, MD, presents insights from a phase 3 trial on post-transplantation cyclophosphamide, tacrolimus, mycophenolate and mofetil prophylaxis vs standard prophylaxis for patients with graft-versus-host-disease.

Javier Bolaños Meade, MD,...

07/10/2023

Oncology

Videos

Analyzing Mechanisms of Pirtobrutinib Resistance Among Patients With CLL Pre-Treated With a Covalent BTK Inhibitor

07/10/2023

Jennifer R. Brown , MD, PhD;

At the 2023 EHA Congress, Jennifer Brown, MD, presented study findings on mechanisms of resistance to pirtobrutinib among patients with chronic lymphocytic leukemia pre-treated with a covalent BTK inhibitor.

At the 2023 EHA Congress,...

07/10/2023

Oncology

Videos

FDA Approval of Epcoritamab for Patients With R/R Diffuse Large B-Cell Lymphoma

07/06/2023

Tycel Phillips ;

Tycel Phillips, MD, shares insights into the recent FDA approval of epcoritamab as a treatment for patients with relapsed/refractory DLBCL not otherwise specified, including indolent lymphoma and high-grade B-cell lymphoma.

Tycel Phillips, MD, shares...

07/06/2023

Oncology

Videos

BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma

06/27/2023

Vincent Ribrag , MD;

At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.

At the 2023 EHA Congress,...

06/27/2023

Oncology

Videos

Acalabrutinib Combined With Bendamustine and Rituximab for Patients With Treatment-Naive or Relapsed/Refractory MCL

06/26/2023

Tycel Phillips ;

Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.

Tycel Phillips, MD, presented...

06/26/2023

Oncology

Carlotta Antoniotti, MD, PhD, University of Pisa

Videos

Atezolizumab With FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer in the First-Line Setting

06/22/2023

Carlotta Antoniotti , MD, PhD;

At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.

At the 2023 ASCO annual meeting,...

06/22/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology